ACM Research (ACMR) CEO gains 545,400 performance-based options as value target hit

Rhea-AI Filing Summary

ACM Research CEO David H. Wang reported the vesting of performance-based stock options tied to the company’s market value. On February 4, 2026, 545,400 stock options with a $7.36 exercise price became exercisable, bringing his total outstanding options to 1,636,197 shares of Class A common stock.

The options were originally granted on March 20, 2020 and vest in three tranches when ACM Research’s market capitalization increases by $1 billion, $2 billion, and $3 billion from $553,383,586 at grant. The latest vesting was triggered when market capitalization first reached or exceeded $3,553,383,586. The filing also lists indirect holdings of Class A common stock through family members and family trusts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wang David H

(Last) (First) (Middle)

C/O ACM RESEARCH, INC.

42307 OSGOOD ROAD, SUITE I

(Street)

FREMONT CA 94539

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACM Research, Inc. [ ACMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock								100,002	I	By Jing Chen, wife of David H. Wang
Class A Common Stock								45,837	I	By Sophia Wang, daughter of David H. Wang
Class A Common Stock								180,000	I	By David Hui Wang and Jing Chen Family Irrevocable Trust for Wang Children
Class A Common Stock								620,001	I	By Wang-Chen Family Living Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.36	02/04/2026		A		545,400		(1)(2)	03/19/2030	Class A Common Stock	545,400	$0	1,636,197	D

Explanation of Responses:

1. On March 20, 2020, the reporting person was granted options to purchase an aggregate of 1,636,197 shares of the Issuer's Class A common stock, based on the satisfaction of certain performance criteria. In general, one-third of the shares subject to the options vest and become exercisable upon an increase in the Issuer's market capitalization (calculated as described in footnote 2) of $1 billion, $2 billion and $3 billion, respectively, from the market capitalization of $553,383,586 on the date of grant. 545,400 shares vested and became exercisable on February 4, 2026, which was the first trading day as of which the Issuer's market capitalization equaled or exceeded $3,553,383,586.

2. For purposes of the options, the market capitalization as of a specified trading day is calculated by multiplying (a) the average of the daily volume-weighted average price per share of the Issuer's Class A common stock for each of the trading days occurring during the thirty calendar day period ending on that specified trading day by (b) the total number of issued and outstanding shares of the Issuer's Class A and Class B common stock as of 11:59 p.m. (Eastern time) on such specified trading day.

Remarks:

Chief Executive Officer, President and Director

	/s/ Mark McKechnie, Attorney-in-Fact for David H. Wang	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ACMR CEO David H. Wang report on February 4, 2026?

David H. Wang reported the vesting of 545,400 performance-based stock options on February 4, 2026. These options became exercisable when ACM Research’s market capitalization reached a preset threshold, increasing his outstanding option holdings to 1,636,197 shares of Class A common stock.

How many ACMR stock options does David H. Wang hold after this Form 4 filing?

After the reported vesting, David H. Wang holds 1,636,197 stock options for ACM Research Class A common stock. These options stem from a March 20, 2020 grant that vests in tranches based on the company achieving specified market capitalization increases over the grant-date level.

What performance conditions triggered David H. Wang’s ACMR option vesting?

The vesting depends on ACM Research’s market capitalization rising by $1 billion, $2 billion, and $3 billion from $553,383,586 at grant. The 545,400 options vested when market capitalization first equaled or exceeded $3,553,383,586, satisfying the highest performance threshold under the grant’s terms.

When were David H. Wang’s ACMR performance stock options originally granted?

The options were granted on March 20, 2020 as a performance-based award covering 1,636,197 shares. Vesting occurs in three tranches as ACM Research’s market capitalization surpasses specified billion-dollar increases from the grant-date market capitalization of $553,383,586.

What indirect ACMR share holdings related to David H. Wang are disclosed in this Form 4?

The filing lists indirect Class A holdings of 100,002 shares by his wife Jing Chen, 45,837 by his daughter Sophia Wang, 180,000 in a family irrevocable trust, and 620,001 in the Wang-Chen Family Living Trust, reflecting family and trust-related ownership positions.

What is the exercise price and expiration date of David H. Wang’s ACMR stock options?

The reported stock options have a $7.36 exercise price per share and an expiration date of March 19, 2030. They were structured as performance-based options, with vesting tied to ACM Research’s market capitalization milestones achieved after the original 2020 grant date.